Cambrex
CBM | US
Overview
Corporate Details
- ISIN(s):
- US1320111073
- LEI:
- 4Q9DLX2VIFGJMOYJ4Y35
- Country:
- United States of America
- Address:
- N/A
- Website:
- https://www.cambrex.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Cambrex filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cambrex
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cambrex via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.
United States of America
IONS
United States of America
IONS
Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.
United States of America
IOVA
United States of America
IOVA
France
IPN
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden
IRLAB
Sweden
IRLAB
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America
IRWD
United States of America
IRWD
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea
086890
South Korea
086890
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America
ITRM
United States of America
ITRM
Develops plant-based, non-opioid GI therapies for humans and animals.
United States of America
JAGX
United States of America
JAGX
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
United States of America
JANX
United States of America
JANX
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan
7774
Japan
7774